Company Overview - IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology and a leading supplier of equipment and services in proton therapy, which is the most advanced form of radiation therapy available today [6] - The company is also a key player in industrial sterilization, radiopharmaceuticals, and dosimetry [6] - IBA is based in Louvain-la-Neuve, Belgium, and employs approximately 2,100 people worldwide [6] - The company is listed on the pan-European stock exchange EURONEXT [7] Upcoming Financial Results - IBA will publish its consolidated results for the half year 2025 on Thursday, 28 August 2025 at 7am CEST [2] - A conference call and webcast will be hosted by IBA's management team on the same day at 3pm CEST, which will include a Q&A session [3] - The presentation will be available on IBA's investor relations website shortly before the call [4]

Core Insights - The Proton Therapy Academy has been launched as a global training initiative to address the growing demand for proton therapy education among healthcare professionals [1][2][3] Industry Overview - Global demand for proton therapy is increasing, yet less than 1% of radiation oncology patients currently receive this treatment, highlighting a significant gap compared to the estimated 15% that could benefit from it [2] - The Academy aims to broaden access to proton therapy through comprehensive education and training programs [3] Company Initiatives - IBA, the leader in particle accelerator technology, is spearheading the Proton Therapy Academy in collaboration with various leading institutions [1][7] - The Academy will serve as a central hub for high-quality educational content, including over 135 videos from proton therapy experts [4] Collaborative Network - The Proton Therapy Academy Network includes prominent cancer treatment institutions from America, Europe, and Asia, which will shape the Academy's training programs [5][6] - The training program will combine theoretical knowledge with practical experience through online courses and on-site training [5][6] Leadership Statements - Prof. Marco Durante emphasized the Academy's role in fostering collaboration and innovation in the field of proton therapy [5] - Olivier Legrain, CEO of IBA, highlighted the initiative's commitment to providing world-class training to oncology professionals globally [5]